Search Result

Pathways Recommended:	Stem Cell/Wnt Cell Cycle/DNA Damage

Results for "

Solid cancer cells

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (7) Autophagy (1) c-Met/HGFR (1) CD3 (1) CDK (2) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (1) DYRK (1) EGFR (2) Epigenetic Reader Domain (1) Eukaryotic Initiation Factor (eIF) (1) HDAC (1) Histone Methyltransferase (1) HSP (1) ICMT (1) Microtubule/Tubulin (1) Mitochondrial Metabolism (1) PD-1/PD-L1 (3) PERK (1) PI3K (2) PPAR (1) TGF-β Receptor (1) Tim3 (1) TNF Receptor (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (24) Inflammation/Immunology (1) Neurological Disease (1)

By Targets:

Apoptosis (7)

Autophagy (1)

c-Met/HGFR (1)

CD3 (1)

CDK (2)

DNA Alkylator/Crosslinker (1)

DNA/RNA Synthesis (1)

DYRK (1)

EGFR (2)

Epigenetic Reader Domain (1)

Eukaryotic Initiation Factor (eIF) (1)

HDAC (1)

Histone Methyltransferase (1)

HSP (1)

ICMT (1)

Microtubule/Tubulin (1)

Mitochondrial Metabolism (1)

PD-1/PD-L1 (3)

PERK (1)

PI3K (2)

PPAR (1)

TGF-β Receptor (1)

Tim3 (1)

TNF Receptor (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (24)

Inflammation/Immunology (1)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Targets Recommended: Nuclear Factor of activated T Cells (NFAT) BCRP

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99406

Petosemtamab MCLA 158	EGFR	Cancer
Petosemtamab (MCLA 158) is an anti- EGFR (K_d: 0.22 nM) and anti-LGR5 (K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads to EGFR signaling blockade and receptor degradation in LGR5+ cancer cells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC) .

HY-P99827

Cobolimab TSR-022; GSK4069889	Tim3	Cancer
Cobolimab (TSR-022) is an anti-TIM-3 monoclonal antibody. Cobolimab mediates the internalization of TIM3 with an IC₅₀ value of 0.4464 nM. Cobolimab has potential application in solid tumors and non-small cell lung cancer (NSCLC) .

HY-146999

YM458	Histone Methyltransferase Epigenetic Reader Domain Apoptosis	Cancer
YM458 is a potent EZH2 and BRD4 dual inhibitor with IC₅₀s of 490 nM and 34 nM, respectively. YM458 inhibits cell proliferation and colony formation and induces cell cycle arrest and apoptosis in solid cancer cells. YM458 can be used for researching anticancer .

HY-N2732

6-Prenylapigenin 6-Prenyl-4',5,7-trihydroxyflavone; 6-C-Prenylapigenin	Others	Cancer
6-Prenylapigenin is a biologically active flavonoid with anti-tumor activity and antiangiogenic properties. 6-Prenylapigenin exerts cytotoxicity against cancer cells, such as leukemia and solid cancer cells .

HY-139453A

LP-284	DNA Alkylator/Crosslinker	Cancer
LP-284 is a potent DNA alkylating agent that kills solid tumours. LP-284 can be used in the studies of hematologic cancers with compromised DNA repair, such as mantle cell lymphoma (MCL) .

HY-157990

Wnt/β-catenin-IN-1	Wnt β-catenin	Cancer
Wnt/β-catenin-in-1 (compounds 17) is a Wnt/β-catenin signaling pathway inhibitor. Wnt/β-catenin-IN-1 can induce apoptosis of colon cancer cells, has broad-spectrum anticancer activity, and can be used for the reseach of a variety of solid tumors .

HY-101991

ML291	PERK Eukaryotic Initiation Factor (eIF) Apoptosis	Cancer
ML291 is a UPR (unfolded protein response)-inducing sulfonamidebenzamide. ML291 overwhelms the adaptive capacity of the UPR and induces apoptosis in a variety of solid cancer models. ML291 can activate the PERK/eIF2a/CHOP (apoptotic) arm of the UPR and reduce leukemic cell burden .

HY-P99422

Adebrelimab SHR-1316	PD-1/PD-L1 Apoptosis	Cancer
Adebrelimab (SHR-1316) is a humanized IgG4 monoclonal PD-L1 (PD-1/PD-L1) antibody. Adebrelimab has promising antitumor activity in solid tumors including extensive-stage small-cell lung cancer (SCLC) .

HY-123938

Risovalisib CYH33	PI3K	Cancer
Risovalisib (CYH33) is an orally active, highly selective PI3Kα inhibitor with IC₅₀s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively. Risovalisib inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. Risovalisib has potent activity against solid tumors .

HY-123938A

CYH33 methanesulfonate	PI3K	Cancer
CYH33 methanesulfonate is an orally active, highly selective PI3Kα inhibitor with IC₅₀s of 5.9 nM/598 nM/78.7 nM/225 nM against α/β/δ/γ isoform, respectively. CYH33 methanesulfonate inhibits phosphorylation of Akt, ERK and induces significant G1 phase arrest in breast cancer cells and non-small cell lung cancer (NSCLC) cells. CYH33 methanesulfonate has potent activity against solid tumors .

HY-15205

Ganetespib Maximum Cited Publications 30 Publications Verification STA-9090	HSP Apoptosis	Cancer
Ganetespib (STA-9090) is a heat shock protein 90 (HSP90) inhibitor which exhibits potent cytotoxicity in a wide variety of hematological and solid tumor cell lines. Ganetespib has antiangiogenic effects in colorectal cancer mediated through inhibition of HIF-1α and STAT3 .

HY-16160

Cysmethynil	Autophagy ICMT	Cancer
Cysmethynil is an Icmt inhibitor(IC₅₀ = 2.4 μM). Cysmethynil inhibites RAS membrane binding and EGF signal transduction. Cysmethynil prevents the cells in the G1 phase and induces autophagy. Cysmethynil inhibits PC3 cells proliferation, has synergistic effect with Paclitaxel (HY-B0015) and Doxorubicin (HY-15142A). Cysmethynil has anti-tumor effects and can be used for solid tumor (such as prostate cancer et al.) research .

HY-150772

Tubulin/HDAC-IN-1	Microtubule/Tubulin HDAC Apoptosis Mitochondrial Metabolism	Cancer
Tubulin/HDAC-IN-1 is a dual tubulin and HDAC-IN-1 inhibitor through CH/π interaction with tubulin and hydrogen bond interaction with HDAC8. Tubulin/HDAC-IN-1 inhibits tubulin polymerization and selectively inhibits HDAC8 (IC₅₀: 150 nM). Tubulin/HDAC-IN-1 has cytotoxicity against various human cancer cells, also arrests cell cycle in the G2/M phase and induces cell apoptosis. Tubulin/HDAC-IN-1 can be used in the research of hematologic and solid tumors such as neuroblastoma, leukemia .

HY-16350

BOLD-100 NKP-1339; IT-139; KP-1339	DNA/RNA Synthesis Apoptosis	Cancer
BOLD-100 (NKP-1339; IT-139) is the first-in-class ruthenium-based anticancer agent in development against solid cancer with limited side effects. BOLD-100 induces G2/M cell cycle arrest, blockage of DNA synthesis, and induction of apoptosis via the mitochondrial pathway. BOLD-100 has a high tumor targeting potential, strongly binds to serum proteins such as albumin and transferrin and activates in the reductive tumor milieu .

HY-P99109

Zimberelimab GLS-010; AB-122; WBP-3055	PD-1/PD-L1	Cancer
Zimberelimab (GLS-010) is a fully human IgG4 anti-PD-1 monoclonal antibody with an EC₅₀ of 210 pM for human PD-1. Zimberelimab effectively blocks the binding of PD-L1 and PD-L2 to cell-surface PD-1 in CHO-S cells, with IC₅₀ values of 580 pM and 670 pM, respectively. Zimberelimab shows antitumor activities, and can be used for various cancers research, including cervical cancer, non-small cell lung cancer and classical Hodgkin’s lymphoma .

HY-128587

Mevociclib 4 Publications Verification SY-1365	CDK	Cancer
Mevociclib (SY-1365) is a potent and first-in-class selective CDK7 inhibitor, with a K_i of 17.4 nM. Mevociclib exhibits anti-proliferative and apoptotic effects in solid tumor cell lines. Mevociclib possesses anti-tumor activity in hematological and multiple aggressive solid tumors .

HY-112296

T025 2 Publications Verification	CDK Apoptosis DYRK	Cancer
T025 is an orally active and highly potent inhibitor of Cdc2-like kinase (CLKs), with K_d values of 4.8, 0.096, 6.5, 0.61, 0.074, 1.5 and 32 nM for CLK1, CLK2, CLK3, CLK4, DYRK1A, DYRK1B and DYRK2, respectively. T025 induces caspase-3/7-mediated cell apoptosis. T025 reduces CLK-dependent phosphorylation. T025 exerts anti-proliferative activities in both hematological and solid cancer cell lines (IC₅₀ values: 30-300 nM). T025 has an anti-tumor efficiency, mainly for MYC-driven disease research .

HY-P99011

Cibisatamab	CD3	Cancer
Cibisatamab (CEA-TCB), a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab (CEA-TCB) triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab (CEA-TCB) can be used for colorectal cancer research .

HY-P99114

Sugemalimab	PD-1/PD-L1	Cancer
Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research .

HY-P99217

Rilotumumab AMG 102	c-Met/HGFR	Cancer
Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research .

HY-136244

PF-06952229 1 Publications Verification	TGF-β Receptor	Cancer
PF-06952229 is a potent, selective and orally active TGFbR1 inhibitor. PF-06952229 specifically binds to TGFbR1 and prevents TGFbR1-mediated signal transduction. PF-06952229 is a promising antineoplastic agent for the study solid tumors, especifically metastatic breast cancer .

HY-P99605

Cinrebafusp alfa PRS 343	EGFR TNF Receptor	Cancer
Cinrebafusp alfa (PRS 343) is a high affinity CD137/HER2 bispecfic anticalin-based drug. Cinrebafusp alfa binds to recombinant human HER2 (K_d=0.3 nM) and human monomeric CD137 (4-1BB; K_d=5 nM). Cinrebafusp alfa facilitates T-cell costimulation by tumor-localized, HER2-dependent 4-1BB clustering and activation, further enhancing T-cell receptor-mediated activity and leading to tumor destruction. Cinrebafusp alfa has the potential for HER2+ solid tumors research .

HY-145804

AZD-9574 1 Publications Verification	PPAR	Neurological Disease
AZD-9574 is a potent and brain penetrant PARP1 inhibitor and shows >8000-fold selectivity for PARP1 compared to PARP2/3/5a/6. AZD-9574 acts by selectively inhibiting and trapping PARP1 at the sites of SSBs. AZD-9574 is an anti-cancer agent and can be used for HRD ⁺ breast cancer and advanced solid malignancies research .

Cat. No.	Product Name	Target	Research Area